Efficacy, safety, and survival findings after <scp>long‐term</scp> follow‐up of <scp>ZGJAK002</scp>: A phase 2 study comparing jaktinib at 100 mg twice daily (<scp>BID</scp>) and 200 mg once daily (<scp>QD</scp>) in patients with myelofibrosis

Yi Zhang, Hu Zhou, Zhongxing Jiang, Dengshu Wu, Junling Zhuang, Wei Li, Qian Jiang, Xiuli Wang, Jinwen Huang, Huanling Zhu, Linhua Yang, Xin Du, Fei Li, Ruixiang Xia, Feng Zhang, Jianda Hu, Yan Li, Yu Hu, Jing Liu, Chenghao Jin, Kai Sun, Zeping Zhou, Liqing Wu, Hewen Yin, Shanshan Suo, Wenjuan Yu, Jie Jin

doi:HTTPS://DOI.ORG/https://doi.org/10.1002/ajh.27245

Efficacy, safety, and survival findings after <scp>long‐term</scp> follow‐up of <scp>ZGJAK002</scp>: A phase 2 study comparing jaktinib at 100 mg twice daily (<scp>BID</scp>) and 200 mg once daily (<scp>QD</scp>) in patients with myelofibrosis

Authors: Yi Zhang, Hu Zhou, Zhongxing Jiang, Dengshu Wu, Junling Zhuang, Wei Li, Qian Jiang, Xiuli Wang, Jinwen Huang, Huanling Zhu, Linhua Yang, Xin Du, Fei Li, Ruixiang Xia, Feng Zhang, Jianda Hu, Yan Li, Yu Hu, Jing Liu, Chenghao Jin, Kai Sun, Zeping Zhou, Liqing Wu, Hewen Yin, Shanshan Suo, Wenjuan Yu, Jie Jin

Published: 2024-02-12

DOI: HTTPS://DOI.ORG/https://doi.org/10.1002/ajh.27245

Keywords: No keywords found.

Abstract:
No abstract found.

Source: